

ORAL COMMUNICATIONS

Machine learning and experimental models:

- EM-01-O Developing an iPSC based in vitro conditional model as a platform for the study of mendelian diseases.
Torralba M., Morillas A., Richaud Y., Kyriacou D., Pineda M., Capellá G., Crespo S., Raya A.
- EM-02-O Encoding gene expression into biological functions using deep learning.
Ruiz-Arenas C., Marín-Goñi I., Ochoa I., Hernaez M., Pérez-Jurado L. A.

Tools for molecular diagnostics:

- MD-01-O Exploring transcriptome diversity of human liver using nanopore sequencing.
Garrido-Rodríguez P., Padilla-Ruiz J., Frutos-Bernal M.D., Cifuentes-Riquelme R., de la Morena-Barrio M.E., Bravo-Pérez C., Vicente V., Lozano M.L., Ramos-Molina B., Corral J., de la Morena-Barrio B.
- MD-02-O Dissection of the largest cohort of structural variants and detection of new mechanisms involved in antithrombin deficiency by nanopore sequencing.
de la Morena-Barro B., Cuenca-Guardiola J., Orlando C., Sanchis-Juan A., García J.L., Padilla J., de la Morena-Barrio M.E., Puruunen M., Stouffs K., Cifuentes R., Bravo-Pérez C., Benito R., Vicente V., Vidal F., Hernandez-Rivas J.M., Ouwehand W.H., Fernández-Breis J.T., Jochmans K., Lozano M.L., Corral J.

Tumor microenvironment:

- TM-01-O A new in vivo model to study the anti-tumorigenic effect of senolysis.
Lalinde-Gutiérrez M., Rodilla V., Pérez Ramos S., Arribas J.
- TM-02-O Melanoma-specific bcl-xL induces proinflammatory macrophage polarization and recruitment through NFkB signaling pathway.
Lucianò A.M., di Martile M., Perez-Oliva A.B., Del Bufalo D., Mulero V.

Molecular bases of diseases:

- MB-01-O Chronic lymphocytic leukemia patient-derived xenograft as a model of clonal evolution towards Richter transformation.
Playa-Albinyana H., Arenas F., Royo R., Giró A., López-Oreja I., López-Guerra M., Beà S., García-Roves P. M., Campo E., Nadeu F., Colomer D.
- MB-02-O Characterization of UBTF-MAML3 as a new marker of metastatic PPGL: in search of a personalized treatment.
Díaz-Talavera A., Calsina B., Monteagudo M., Martínez-Montes A. M., Mellid S., Letón R., Gil E., Cascón A., Montero-Conde C., Leandro-García L. J., Robledo M.

New therapeutic approaches:

- TA-01-O Aptamers as delivery agents for RNA-based therapies against Multiple Myeloma.
Amundarain A., Cartón-García F., Carrasco-León A., Garate L., Miranda E., San José-Enériz E., Villanueva H., Pastor F., Prósper F., Agirre X.
- TA-02-O Selective protein degradation using camelid nanobodies as a potential therapeutic approach for rare dominant-retinal dystrophies.
Gómez-Escribano A.P., Vázquez-Manrique R.P., García-García G., Millán J.M.

Biomarkers

- B-01-O Assessment of CD5 and CD6 expression levels in PBMCs as potential biomarkers in advanced-stage NSCLC patients treated with immunotherapy.
Moreno-Manuel A., Torres S., Calabuig-Fariñas S., Boada A., Bellón M. L., Escorihuela E., Lozano F., Sirera R., Camps C., Blasco A., Jantus-L.
- B-02-O Immune biomarkers of survival in Multiple Myeloma (MM) patients treated with Lenalidomide and dexamethasone (Rd).
Maia C., Puig N., Pérez C., Cedena M. T., Guerrero C., Larrayoz M., Botta C., Gutiérrez N. C., Calasanz M. J., Martín-Ramos M. L., Hernández M. T., Rosiñol L., González E., de Arriba F., Oriol A., González-Calle V., Escalante F., de la Rubia J., Gironella M., Ríos R., García-Sánchez R., Arguiñano J. M., Alegre A., Martín J., Couto M. C., Casanova M., Arnao M., Pérez E., Garzón S., González M. S., Martín G., Rossi A. C., Coleman M., Encinas C., Vale A. M., Terruel A. I., Martínez-Climent J. A., Lahuerta J. J., Bladé J., Niesvizky R., San-Miguel J. F., Mateos M. V., Paiva B.

POSTER PRESENTATIONS

Machine learning and experimental models:

- EM01 Role of calcitriol on the differentiation of human colon normal organoids.
Albadea-Rodríguez D., Bustamante-Madrid P., Barbáchano A., Rodríguez-Cobos J., Larriba MJ., Lafarga M., Muñoz A., Fernández-Barral A.
- EM02 Patient-derived organoids as a preclinical platform to improve the treatment for head and neck squamous cell carcinomas.
Álvarez-González M., Pozo-Agundo E., Corte D., Villacé Gallego A., Pedregal-Mallo D., López F., Astudillo A., García-Pedrero J.M., Rodrigo J. P., Álvarez-Fernández M.
- EM03 AlphaFold predictions for mutations affecting proteins with conformational flexibility or without crystal structure resolution.
Garrido-Rodríguez P., Carmena-Bargueño M., de la Morena-Barrio M. E., Bravo-Pérez C., de la Morena-Barrio B., Cifuentes-Riquelme R., Vicente V., Lozano M. L., Pérez-Sánchez H., Corral J..
- EM04 Development of a Digital Image Analysis pipeline to differentiate between center and periphery according to morphological characteristics.
Stoks M., Vieco-Martí L., Granados-Aparici S., Navarro S., Noguera R.

Tools for molecular diagnostics:

- MD01 T-prolymphocytic leukemia: Th-associated immunophenotype of tumor cells and distribution of residual immune cells in blood.
Morán-Plata F.J., Muñoz-García N., Mateos S., Barrena S., Barba-Domínguez F., Yeguas A., Carretero-Domínguez S., Orfao A., Almeida J.
- MD02 Design and validation of a cost-effective tool for the detection of microsatellite instability in blood of CMMRD patients.
Kyriacou D., Canet J., Wimmer K., Rueda D., Pastor A., González-Granado L.I., Capellá G., Marín F., Pineda M.

- MD03 VaRHC: an R package for semi-automate ACMG/AMP variant classification on hereditary cancer genes according to gene-specific ClinGen guidelines.
Munté E., Feliubadaló L., Pineda M., Gonzalez M., Tornero E., Roca C., Moreno-Cabrera J.M., Bales J., Mosquera J.L., Lázaro C.
- MD04 A method for detection of uniparental disomy from exome and genome sequencing data and its diagnostic implications.
Sevilla Porras M., Ruiz-Arenas C., Díes Curiá C., Flores-Peirats R., Bullich G., Pujol A., Schluter A., Armstrong J., Valenzuela I., Ribes A., Tort F., Pérez-Jurado L.A.

Tumor microenvironment:

- TM01 Immune profile analysis of Follicular Lymphoma lymph node biopsies reveals CD70 as a bad prognosis marker and a potential target.
Araujo-Ayala F., Mozas P., Villalba M., Rivero A., López-Guillermo A., Magnano L., De Andrea C.E., Pérez-Galán P.
- TM02 Functional insight into the reciprocal paracrine crosstalk of stromal fibroblasts in the head and neck cancer microenvironment.
Prieto-Fernandez L., Montoro-Jiménez I., Otero-Rosales M., Hermida-Prado F., García-Inclán C., Villaronga M.A., Menéndez S.T., Calvo F., Rodrigo J.P., Rodríguez-Santamarta T., García-Pedrero J.M., Álvarez-Teijeiro S.
- TM03 Inhibition of the MNK1/2 pathway enhances the anti-tumour immune response in breast cancer.
Cano-Galietero M., Jiménez-Lasheras B., Alvarez-de la Sierra D., Palazon A., Hümmer S., Ramón y Cajal S.
- TM04 Notch signaling induces a hematopoietic stem cell quiescence state during fetal development.
Herrero Molinero P., Maqueda Gonzalez M., Espinosa Blay L., Bigas Salvans A.

Molecular bases of diseases:

- MB01 AIRAPL and AIRAP are key proteostatic factors in the generation of myeloproliferative syndromes.
Maeso D., Bretones G., Santiago-Fernández O., Pérez-Freije J. M., López-Otín C.

Abstract List – V YOUNG RESEARCHERS MEETING

14th-15th November 2022 | Santiago de Compostela

ciberonc
ciberer

- MB02 PRC2-dependent and NF- κ B-independent I κ B α function is required for pluripotency exit and differentiation.
Galán Palma L., Álvarez-Villanueva D., Iglesias A., Barrero M., Maqueda M., Bertrán J., Alvarez-Erriico D., García-Prieto C. A., Rodríguez-Cortez V., Bueno C., Vidal A., Villanueva A., Menéndez P., Payer B., Esteller M., Espinosa L., Bigas A.
- MB03 Essential contribution of IKK α and NEMO in the recognition of DNA damaged sites by active ATM.
Alonso-Marañón J., Sabidó E., Borrás E., Bigas A., Espinosa L.
- MB04 Deciphering IKK α contribution to metastasis mechanisms associated with collective migration.
Alvarez D., Villanueva A., Bigas A., Espinosa L.
- MB05 Molecular characterization of familial pancreatic cancer through NGS and liquid biopsy.
Barreto E., Migoyo C., Carrato Mena A., Earl J.
- MB06 Retrotransposon insertions: a challenging detection and characterization solved by long-read nanopore sequencing - Relevance in antithrombin deficiency.
De la Morena-Barrio B., Cuenca-Guardiola J., Garrido-Rodríguez P., Sanchis-Juan A., De la Morena-Barrio M. E., Cifuentes R., Bravo-Pérez C., Padilla J., Miñano A., Vidal F., Vicente V., Lozano M. L., Ouweland W. H., Fernández-Breis J. T., Corral J.
- MB07 Exploring the transcriptional profile of acute promyelocytic leukemia.
Fernández-Blanco B., Liquori A., Ibáñez Company M., Guaita-Céspedes M., Morote-Faubel M., Garcia-Ruiz C., González Romero E., Sanjuan-Pla A., Sargas Simarro C., Martínez-Valiente C., Avetisyan G., Santiago Balsera M., Díaz-González A., Such Taboada E., Sanz M. A., De la Rubia J., Montesinos Fernández P., Barragán González E., Cervera Zamora J.
- MB08 An integrated multi-omic strategy to identify splice-altering variants in myeloid neoplasms.
Guaita-Céspedes M., Liquori A., Fernández-Blanco B., Morote-Faubel M., Garcia-Ruiz C., Sanjuan-Pla A., Avetisyan G., Santiago Balsera M., Díaz A., Such Taboada E., Sanz Santillana G., De la Rubia J., Montesinos Fernández P., Barragán González E., Cervera Zamora J.

Abstract List – V YOUNG RESEARCHERS MEETING

14th-15th November 2022 | Santiago de Compostela

ciberonc
ciberer

- MB09 Desmoplastic small round cell tumor, EWSR1::WT1, transcription factors.
Lobo L., Olmedo J., Rodríguez C., Alonso J., Rodríguez R., de Álava E., Amaral A. T., Carmen Salguero C.
- MB10 Refining the genetic landscape of Aggressive B-cell lymphoma in children and young adults by a morphological and molecular integrative approach.
Mato S., Salmerón-Villalobos J., Castrejón de Anta N., Ramis-Zaldivar J. E., Colmenero A., Garcia N., Wang L., Verdú J., Andrés M., Celis V., Ortega M. J., Campo E., Balagué O., Salaverria I.
- MB11 Characterization of ncRNA-dependent MEK activity in melanoma.
Molina-Carreño D., Varela I., Crespo P., Herrero A.
- MB12 SOS-RAS GEFs as potential therapeutic targets in cancer and adipose tissue disorders.
OlarTE San Juan A., García-Navas R., Fuentes Mateos R., Fernández Medarde A., Baltanás F. C., Gómez C., Santos E.
- MB13 Multi-omics approach identifies altered molecular pathways in MECP2 duplication syndrome and Rett syndrome Spanish patients.
Pascual-Alonso A., Xiol C., Smirnov D., Kopajtich R., Ludwig C., Prokisch H., Armstrong J.
- MB14 Chromosomal rearrangements in MYC-negative, 11q-negative, CAYA-DLBCL: from cytogenetics to high-resolution detection through mate pair whole genome sequencing AIRAPL and AIRAP are key proteostatic factors in the generation of myeloproliferative syndromes.
Salmerón-Villalobos J., Ramis-Zaldivar J. E., Mato S., Balagué O., Nadeu F., Martín-Guerrero I., Gonzalez-Farré B., Puente X., Diaz-Navarro A., Castrejón de Anta N., Garcia N., Andres M., Verdú-Amorós J., Astigarraga I., Quiroga E., Celis V., Campo E., Salaverria I.
- MB15 Evaluation of the pathogenicity of the m.9176T>C common mutation in the mitochondrial complex V.
Serrano-Lorenzo P., Garrido-Moraga R., Blázquez A., González-Quintana A., García-Consuegra I., Ugalde C., Morán M., Arenas J., Martín M. A.
- MB16 Study of IGHV sequences in low count monoclonal B-cell lymphocytosis versus chronic lymphocytic leukemia.
Manuel Serrano Lozano J., Rodríguez Caballero A., Criado García I., Fuentes Herrero B., Oliva Ariza G., Almeida J., Orfao A.

MB17 Transcriptional and genomic characterization of measurable residual disease (MRD) in acute myeloid leukemia (AML).

Simoes C., Villar S., Ariceta B., Garcés J. J., Burgos L., Alignani D., Sarvide S., Martínez-Cuadrón D., Bergua J. M., Vives S., Algarra L., Tormo M., Martínez P., Serrano J., Herrera P., Ramos F., Salamero O., Lavilla E., Gil C., Lopez-Lorenzo J. L., Vidriales M. B., Chillón C., Labrador J., Falantes J. F., Sayas M. J., Ayala R., Martínez-Lopez J., Alfonso Pierola A., Calasanz M. J., Prosper F., San-Miguel J. F., Sanz M. A., Paiva B., Montesinos P.

MB18 Identification of molecular signatures and pathways involved in Rett syndrome-spectrum disorders using a multi-omics approach.

Xiol C., Pascual-Alonso A., Smirnov D., Kopajtich R., Ludwig C., Prokisch H., Armstrong J.

New therapeutic approaches:

TA01 Validation of combination partners for RAsf1 ablation in advanced lung tumors driven by Kras^{G12V}/Trp53 mutations.

Fernández-Rodríguez A., Musteanu M. and Barbacid M.

TA02 Unveiling the impact of intra-tumor heterogeneity in treatment response to achieve personalized medicine for endometrial cancer patients.

Villafranca-Magdalena B., Denizli M., Masferrer-Ferragutcasas C., Lopez-Gil C., Rebull M., Parra G., García A., Cabrera S., Gil-Moreno A., Moiola C.P. and Colas E.

TA03 Gasdermin B over-expression modulates HER2-targeted therapy resistance by inducing protective autophagy through Rab7 activation.

Ramos-Nebot C., Gámez-Chiachio M., Molina-Crespo A., Morales S., Martínez L., Sarrió D., Moreno-Bueno, G.

TA04 EGFR inhibitors as a therapy for HNSCC in Fanconi anemia: mechanisms of resistance.

Cavero D., Minguillón J., Surrallés J.

TA05 Nano-encapsulation enhances the safety and therapeutic potential of mithramycin for the treatment of sarcomas.

Murillo D., Estupiñán O. Niza E., Bravo I. Rey V., Tornín J. Gallego B. Huergo C. Alonso-Moreno C., Rodríguez R.

Abstract List – V YOUNG RESEARCHERS MEETING

14th-15th November 2022 | Santiago de Compostela

ciberonc
ciberer

- TA06 Preventing intercellular communication through the ITGav/ITGB3/HSPGs axis in metastatic cancer.
Muro-Blanc E., Hümmer S., Ramón y Cajal S.
- TA07 Study of the biological effect of lipid nanoemulsions in a lung cancer model.
Ramos-Docampo E., García-Fernández J., Mármol-Peguero I., Morín-Jiménez I., Aguiar-Fernández P., de la Fuente-Freire M.
- TA08 Developing a high throughput screening to identify RAF1 degraders as a therapeutic approach in KRAS-driven lung tumors.
Aizpurua G., de-la-Puente-Ovejero L., García-Alonso S., Barbacid M.
- TA09 AURKA-P53 pathway status analysis in vitro as affected by the combination of APR-246 plus carboxellin in cancer cell lines.
Martinez-Pretel J.J., Egeuz K., Sanchez-Serrano P., Perez-Fidalgo J.A., Pineda B.
- TA10 Building insights into CDC37-RAF1 interaction: a new opportunity to treat KRAS driven tumors.
de-la-Puente-Ovejero L., Aizpurua G., Lechuga C.G. García-Alonso S., Barbacid M.
- TA11 KSR signaling is implicated in resistance to KRAS inhibitors.
Brehey O., Paniagua G., Jacob H.K.C., García-Alonso A. Lechuga C.G., Pons T., Musteanu M., Guerra C., Drosten M., Barbacid M.
- TA12 Differential antitumoral response to Met inhibition in combination with chemo-immunotherapy in Small Cell Lung Cancer syngeneic mouse models
Del Rey-Vergara R., Galindo-Campos M.A., Rocha P., Martínez C., Carpes M., Menéndez S., Rossell A., Taus A., Rovira A., Arriola E.
- TA13 Exploring therapeutic approaches against advanced pancreatic tumors.
Barrambana S., Liaki V., González M.C., Álvarez R., Barbacid M., Guerra C.
- TA14 GSDMB isoforms differentially control pyroptotic cell death and mitochondrial damage in cancer cells.
Colomo S., Oltra S.S., Sin L., Pérez-López M., Molina-Crespo A., Choi K.H., Martinez L., Morales S., González-Paramos C., Orantes A., Lázaro S., Soriano M., Hernandez A., Ko J.K., Sarrió D., Moreno- Bueno G.

Biomarkers:

- B01 Comprehensive characterization of human lung squamous cell carcinoma identifies high expression of TFRC as a mark of poorly immunogenic tumours.
Gutiérrez-Pérez M., Ramos-Paradas J., Gomez-Sanchez D., García-Luján R., Zugazagoitia J., Carrizo N., Enguita A.B., Conde E., Garrido-Martin E.M., Uceró A.C., Paz-Ares L.
- B02 Amplification of both SOX2 and PIK3CA genes at 3q26 as an early predictor of laryngeal cancer risk.
Montoro-Jiménez I., Granda-Díaz R., Menéndez S.T., Otero-Rosales M., Prieto-Fernández L., Rodríguez A., López-Fernández A., García-de-la-Fuente V., Álvarez-Teijeiro S., Hermida-Prado F., Rodrigo J.P., García-Pedrero J.M.
- B03 Identification of novel tissue and plasma-based protein biomarkers for early lung cancer prognosis.
Orive D., Pasquier A., Adradas V., Zugazagoitia J., Paz-Ares L., Valencia K., Montuerga L.M.
- B04 Role of GPX1 as a stemness and prognostic factor in sarcomas.
Huergo C., Estupiñán O., Lavoie J., Gao J., González M.V., Blanco V., Gallego B., Murillo D., Rey V., Tornín J., Rodríguez R.
- B05 Deciphering the potential of CD44v6 as biomarker and therapeutic target in bladder cancer.
Lodewijk L., Rubio C., Reina I.A., Alonso-Sánchez M., Alberquilla O., Sánchez-Domínguez R., García-Martin R., Parrilla L., Paramio J.M., Dueñas M.
- B06 Soluble immune-related factors are associated with response to neoadjuvant chemotherapy in triple-negative breast cancer.
Boada-Acosta A., Torres-Martínez S., Núñez M., Escorihuela E., García-García J.A., Godes M.J., Camps C., Jantus-Lewintre E., Iranzo V., Calabuig-Fariñas S.
- B07 sGalectin-3, sIL-10, sMIP3a and sIL13 as prognostic biomarkers in triple-negative breast cancer.
Boada-Acosta A., Torres-Martínez S., Núñez M., Escorihuela E., García-García J.A., Godes M.J., Camps C., Iranzo V., Jantus-Lewintre E., Calabuig-Fariñas S.
- B08 TCR-β repertoire analysis to identify predictive and prognostic biomarkers in Non-Small Cell Lung Cancer patients treated with anti-PD1.
Moreno-Manuel A., Dong N., Torres S., Gallach S., Mosqueda M., Castilla E., Calabuig-Fariñas S., Sirera R., Blasco A., Camps C., Jantus-Lewintre E.



Abstract List – V YOUNG RESEARCHERS MEETING

14th-15th November 2022 | Santiago de Compostela

ciberonc
ciberer

- B09 Identification of a GSDMB-related pyroptotic signature as a predictive and prognostic biomarker in cancer.
Oltra S.S., Colomo S., Lázaro S., Triviño J.C., Sarrió D., Moreno-Bueno G.
- B10 Clinical and biological relevance of Anoctamin-1 in head and neck squamous cell carcinomas.
Otero-Rosales M., Menéndez S.T., Granda-Díaz R., Prieto-Fernández L., Montoro-Jiménez I., Santos L., Vallina A., Allonca E., Álvarez-Teijeiro S., Rodríguez R., Rodrigo J.P., García-Pedrero J.M., Hermida-Prado F.
- B11 Cell cycle regulators as biomarkers for radiotherapy: role of the mitotic kinase mastl/greatwall.
Pozo-Agundo E., Álvarez-González M., García-de-la-Fuente V., Villacé-Gallego A., de Martino A., Rodrigo J.P., García-Pedrero J.M., Álvarez-Fernández M.
- B12 Immunotherapy biomarkers for Triple Negative Breast Cancer.
Ramos Navas L.A., López Henríquez R., Salido E.
- B13 CTCs expression analysis predicts response to polytherapy in luminal metastatic breast cancer patient.
González-Conde M., Yañez-Gómez C., Abuín C., Cueva J., Palacios P., Rodríguez C., López-López R., Costa C.